Skip to main content
. 2017 Apr 7;31(5):668–676. doi: 10.1038/eye.2017.42

Figure 5.

Figure 5

The level of serum extraocular muscle antibodies and efficacy in evaluation of the treatment of active TAO. (a) The concentration of calsequestrin antibody in active TAO patients was significantly higher than that in inactive TAO, GD patients, and normal controls (*P<0.05). Compared with normal controls, the level of UACA antibodies in patients with TAO and GD were higher (#P<0.05). Serum G2s antibody levels showed no difference between the groups (P>0.05). (b) After treatment, both serum calsequestrin antibody and CAS in active TAO patients decreased significantly (*P<0.05, #P<0.05).